Ticker	Current Price	Change
IBB	320.74	0.63 (0.2%)
XBI	80.31	1.11 (1.4%)
CNCR	23.70	0.3 (1.26%)

New Products

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

Editor's note

Cheers! Endpoints News turns 1 today — and we're unwrapping info on a new subscription plan

FDA, Manufacturing

The closest thing to a shoo-in Pfizer has ever handed to the FDA just got rejected

Latest

FDA OKs Portola’s anticoagulant betrixaban for preventing blood clots →

OvaScience and Active Biotech name new CEOs, Valeant adds John Paulson to the board →

PhIII-focused Cara sees shares spike on its new ‘breakthrough’ status at the FDA →

CRISPR crew’s lab test spotlights lead program in sickle cell disease, beta-thalassemia →

Bluebird bio steps up with a promising snapshot of its gene therapy upgrade →

The Endpoints 100 CEO Survey: Execs offer a big thumbs up for Gottlieb and some suggestions for making the FDA a better agency →

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD →

Top News

FDA padlocks any new human tests on Seattle Genetics’ cancer drug in the wake of more deaths

John Carroll

UPDATED: Novartis’ big PhIII for canakinumab scores a surprise win helping heart attack patients

John Carroll

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

John Carroll

More news

Protocols

Quick hits from around the biopharma web

Jun 23

Merck KGaA gets a thumbs up for once-dead MS drug; Aveo shares soar as tivo makes a comeback

Jun 22

Patrick Soon-Shiong accused of more conflicts of interest; Eli Lilly expands in San Diego

Jun 21

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment

Jun 20

In wake of a trial disaster, Seattle Genetics files sBLA; Egalet takes a dive on a CRL

More Protocols

Thumbs Up/Down

Jun 16

From bombs to bromides? Trump’s jousting with biopharma may well boil down to a handshake on drug prices

Jun 9

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget

Jun 2

Thumbs up: Cancer drug R&D is exploding, get ready for the pricing debate to follow

May 26

Some worthy initiatives out of the FDA fall far short of an effective federal plan to rein in drug prices

More Thumbs Up/Down

Special Reports

The 15 top R&D spenders in the global biopharma business: 2016

Top 10 pipeline blowups, setbacks and snafus in H1 2016

Where the money is: Biotech’s megahubs command VC's billions

Deep dives

Optimizing clinical outcomes for challenging molecules with lipid-based drug delivery

What’s a biotech CEO worth? The top 15 pay packages puts a spotlight on performance — usually

A biotech billionaire tops the list of the 15 highest paid R&D execs in biopharma

The top 15 spenders in the global drug R&D business: 2017

Planning a clinical supply program? Don’t overlook primary packaging.

Alzheimer’s: Learning From a Legacy of Bitter Setbacks

Marco

Hot BioTwitter bot - last updated ago

Most Viral

Insurers Battle Families Over Costly Drug for Fatal Disease

New York Times Katie Thomas a day

Notes from ASCO 2017 - another year of stagnation

Open Reading Frame Ohad Hammer a day

Bevyxxa Label

FDA a day

Bluebird Bio's gene therapy for blood disorders yields some impressive results ― but also raises questions

STAT a day

Joe Biden's beef with Bill Ackman sparks heated exchange and presidential chatter

Fox Business Charlie Gasparino a day

Summary of opinion (initial authorization) for Fotivda (tivozanib hydrochloride monohydrate)

EMA a day

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

Novartis a day

FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients

FDA a day

Bluebird bio steps up with a promising snapshot of its gene therapy upgrade

ENDPOINTS NEWS John Carroll a day

FDA OKs Portola's anticoagulant betrixaban for preventing blood clots

ENDPOINTS NEWS John Carroll a day

Latest

WSJ

GOP Senators Lay Out Demands on Health Bill

WSJ

New York Hospitals Turn to Modular Construction to Speed Projects

WSJ

A 13-Year-Old Math Whiz on the Best Calculators and Online-Chess Sites

Bloomberg

Nestle Said to Be Targeted by Activist Dan Loeb's Third Point

Forbes

How Medical Centers And Pharmas Respond To Technological Innovation: The Four Rs

WSJ

Health Bill Provision Favors States That Didn't Expand Medicaid

WSJ

One of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a Cure

Bloomberg

Millennial Men Are Bolstering the Plastic Surgery Industry

WSJ

Jury Selection to Begin in Martin Shkreli Trial

Journal of Clinical Oncology

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Hot This Week

1

New York Times

Draft Order on Drug Prices Proposes Easing Regulations

2

Senate

H. R. 1628

3

New York Times

Insurers Battle Families Over Costly Drug for Fatal Disease

4

Open Reading Frame

Notes from ASCO 2017 - another year of stagnation

5

Novartis

Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack

6

WSJ

When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War

7

CNBC

Trump drug pricing order may be weeks away

8

FDA

Bevyxxa Label

9

Forbes

Novartis Drug Becomes First To Prevent Heart Attacks And Strokes By Targeting Inflammation

10

ENDPOINTS NEWS

Massachusetts governor Charlie Baker unveils a $500M program to keep its big biotech hub booming

Follow Marco

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

Cheers! Endpoints News turns 1 today — and we're unwrapping info on a new subscription plan

The closest thing to a shoo-in Pfizer has ever handed to the FDA just got rejected

Latest

FDA OKs Portola’s anticoagulant betrixaban for preventing blood clots →

OvaScience and Active Biotech name new CEOs, Valeant adds John Paulson to the board →

PhIII-focused Cara sees shares spike on its new ‘breakthrough’ status at the FDA →

CRISPR crew’s lab test spotlights lead program in sickle cell disease, beta-thalassemia →

Bluebird bio steps up with a promising snapshot of its gene therapy upgrade →

The Endpoints 100 CEO Survey: Execs offer a big thumbs up for Gottlieb and some suggestions for making the FDA a better agency →

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD →

Top News

Protocols

Thumbs Up/Down

Special Reports

The 15 top R&D spenders in the global biopharma business: 2016

Top 10 pipeline blowups, setbacks and snafus in H1 2016

Where the money is: Biotech’s megahubs command VC's billions

Deep dives

Optimizing clinical outcomes for challenging molecules with lipid-based drug delivery

What’s a biotech CEO worth? The top 15 pay packages puts a spotlight on performance — usually

A biotech billionaire tops the list of the 15 highest paid R&D execs in biopharma

The top 15 spenders in the global drug R&D business: 2017

Planning a clinical supply program? Don’t overlook primary packaging.

Alzheimer’s: Learning From a Legacy of Bitter Setbacks

Most Viral

Latest

Hot This Week

Contact Endpoints News